Online Program Home
My Program

Abstract Details

Activity Number: 530
Type: Topic Contributed
Date/Time: Wednesday, August 3, 2016 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract #320281 View Presentation
Title: Facilitating Clinical Trial Simulation in Alzheimer's Disease Using the CAMD IPD, Literature Summary Level Data, and the 'adsim' R Package
Author(s): Daniel Polhamus*
Companies: Metrum Research Group
Keywords: Alzheimer's Disease ; Meta analysis ; trial simulation ; CAMD ; CODR ; AD

The inability to stop or prevent the progression of Alzheimer's Disease (AD) has been well been documented, expensive, and frustrating. It has, however, bred collaboration and innovation rarely seen in industry. To facilitate trial optimization, a coalition (CAMD) provided placebo-arm patient level data for 6500 patients over 24 clinical trials of AD and MCI (the CODR database) and funded development of a clinical trial simulation tool (R::adsim). A disease-drug-trial model for Alzheimer's Disease was developed based on joint modeling of literature meta-data and CODR, summarizing available evidence with regard to rates of natural progression, placebo effects, and drug effects for marketed therapeutics [Rogers et al., 2012]. The adsim package implement the model to simulate longitudinal ADAS-cog data based upon patient baseline information. Hypothesized drug effects may be specified in a flexible manner, potentially including disease modifying components that are expressed relative to progression rates. Simulation of ADAS-cog trial results is then straightforward for a variety of designs that are typically of interest in stages of development ranging from phase 2a to phase 3.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

Copyright © American Statistical Association